{"id":346,"date":"2020-12-31T10:03:48","date_gmt":"2020-12-31T08:03:48","guid":{"rendered":"https:\/\/mcselena.com\/?page_id=346"},"modified":"2026-09-25T08:30:42","modified_gmt":"2026-09-25T05:30:42","slug":"infekciozni-bolesti","status":"publish","type":"page","link":"https:\/\/mcselena.com\/index.php\/infekciozni-bolesti\/","title":{"rendered":"\u0414\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0430 \u043d\u0430 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u043e\u0437\u043d\u0438 \u0431\u043e\u043b\u0435\u0441\u0442\u0438"},"content":{"rendered":"\n

\u0414\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0430 \u043d\u0430 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u043e\u0437\u043d\u0438 \u0431\u043e\u043b\u0435\u0441\u0442\u0438<\/h2>\n\n\n
\u041d\u0430\u0438\u043c\u0435\u043d\u043e\u0432\u0430\u043d\u0438\u0435 \u043d\u0430 \u0443\u0441\u043b\u0443\u0433\u0430\u0442\u0430<\/th>\u0426\u0435\u043d\u0430<\/th><\/tr><\/thead>
\u0421\u0438\u0444\u0438\u043b\u0438\u0441 (anti-Syphilis)<\/td>4,09 \u20ac<\/td><\/tr>
anti-T.pallidum IgG-Immunoblot (\u0421\u0438\u0444\u0438\u043b\u0438\u0441-\u0438\u043c\u0443\u043d\u043e\u0431\u043b\u043e\u0442)<\/td>33,23 \u20ac<\/td><\/tr>
Anti-Syphilis - TPHA<\/td>6,39 \u20ac<\/td><\/tr>
\u0421\u041f\u0418\u041d ( anti - HIV 1\/2 antibodies )<\/td>6,14 \u20ac<\/td><\/tr>
\u0425\u0435\u043f\u0430\u0442\u0438\u0442 \u0410 ( anti-HAV IgM )<\/td>7,67 \u20ac<\/td><\/tr>
\u0425\u0435\u043f\u0430\u0442\u0438\u0442 \u0410 ( anti-HAV total )<\/td>7,67 \u20ac<\/td><\/tr>
\u0425\u0435\u043f\u0430\u0442\u0438\u0442 E (anti-HEV IgM )<\/td>8,90 \u20ac<\/td><\/tr>
\u0425\u0435\u043f\u0430\u0442\u0438\u0442 \u0415 ( anti-HEV IgG )<\/td>8,90 \u20ac<\/td><\/tr>
\u0425\u0435\u043f\u0430\u0442\u0438\u0442 \u0415 ( anti-HEV IgM ) Immunoblot<\/td>52,15 \u20ac<\/td><\/tr>
\u0425\u0435\u043f\u0430\u0442\u0438\u0442 \u0415 ( anti-HEV IgG ) Immunoblot<\/td>52,15 \u20ac<\/td><\/tr>
\u0425\u0435\u043f\u0430\u0442\u0438\u0442 \u0412 ( HBsAg )<\/td>7,67 \u20ac<\/td><\/tr>
HBsAg ( quantitative test ) \u043a\u043e\u043b\u0438\u0447\u0435\u0441\u0442\u0432\u0435\u043d \u0442\u0435\u0441\u0442<\/td>15,34 \u20ac<\/td><\/tr>
anti HBsAg<\/td>7,67 \u20ac<\/td><\/tr>
anti HBc IgM<\/td>7,67 \u20ac<\/td><\/tr>
anti HBc total<\/td>7,67 \u20ac<\/td><\/tr>
HBeAg<\/td>7,67 \u20ac<\/td><\/tr>
anti HBeAg<\/td>7,67 \u20ac<\/td><\/tr>
\u0425\u0435\u043f\u0430\u0442\u0438\u0442 \u0412 \u043a\u043e\u043b\u0438\u0447. \u0414\u041d\u041a ( HBV DNA quantitative )<\/td>82,83 \u20ac<\/td><\/tr>
\u0425\u0435\u043f\u0430\u0442\u0438\u0442 \u0421 ( anti-HCV antibodies )<\/td>7,67 \u20ac<\/td><\/tr>
anti-HCV by Immunoblot (\u0425\u0435\u043f\u0430\u0442\u0438\u0442 C-\u0438\u043c\u0443\u043d\u043e\u0431\u043b\u043e\u0442)<\/td>60,33 \u20ac<\/td><\/tr>
HCV \u043a\u043e\u043b\u0438\u0447.\u0420\u041d\u041a ( HCV RNA quantitative )<\/td>96,63 \u20ac<\/td><\/tr>
\u0425\u0435\u043f\u0430\u0442\u0438\u0442 D ( anti-HDV total )<\/td>10,74 \u20ac<\/td><\/tr>
\u0425\u0435\u043f\u0430\u0442\u0438\u0442 D ( anti-HDV IgM )<\/td>10,74 \u20ac<\/td><\/tr>
\u0425\u043b\u0430\u043c\u0438\u0434\u0438\u044f \u0442\u0440\u0430\u0445\u043e\u043c\u0430\u0442\u0438\u0441 (Chlamydia trach.) IgA<\/td>8,69 \u20ac<\/td><\/tr>
\u0425\u043b\u0430\u043c\u0438\u0434\u0438\u044f \u0442\u0440\u0430\u0445\u043e\u043c\u0430\u0442\u0438\u0441 (Chlamydia trach.) IgM<\/td>8,69 \u20ac<\/td><\/tr>
\u0425\u043b\u0430\u043c\u0438\u0434\u0438\u044f \u0442\u0440\u0430\u0445\u043e\u043c\u0430\u0442\u0438\u0441 (Chlamydia trach.) IgG<\/td>8,69 \u20ac<\/td><\/tr>
Chlamidia \u0414\u041d\u041a - PCR \u0442\u0435\u0441\u0442 \u043e\u0447\u0435\u043d \u0441\u0435\u043a\u0440\u0435\u0442<\/td>20,45 \u20ac<\/td><\/tr>
Chlamidia \u0414\u041d\u041a - PCR \u0442\u0435\u0441\u0442 \u0446\u0435\u0440\u0432\u0438\u043a\u0430\u043b\u0435\u043d \u0441\u0435\u043a\u0440\u0435\u0442<\/td>20,45 \u20ac<\/td><\/tr>
Chlamidia \u0414\u041d\u041a - PCR \u0442\u0435\u0441\u0442 \u0443\u0440\u0435\u0442\u0440\u0430\u043b\u0435\u043d \u0441\u0435\u043a\u0440\u0435\u0442<\/td>20,45 \u20ac<\/td><\/tr>
Chlamidia \u0414\u041d\u041a - PCR \u0442\u0435\u0441\u0442 \u0443\u0440\u0438\u043d\u0430<\/td>20,45 \u20ac<\/td><\/tr>
Chlamidia \u0414\u041d\u041a - PCR \u0442\u0435\u0441\u0442 \u0441\u0442\u0430\u0432\u0435\u043d \u043f\u0443\u043d\u043a\u0442\u0430\u0442<\/td>20,45 \u20ac<\/td><\/tr>
Chlamidia \u0414\u041d\u041a - PCR \u0442\u0435\u0441\u0442 \u0435\u044f\u043a\u0443\u043b\u0430\u0442<\/td>21,99 \u20ac<\/td><\/tr>
\u0411\u044a\u0440\u0437 \u0442\u0435\u0441\u0442 Sars-Cov-2<\/td>5,11 \u20ac<\/td><\/tr>
\u041a\u043e\u043c\u0431\u0438\u043d\u0438\u0440\u0430\u043d \u0431\u044a\u0440\u0437 \u0442\u0435\u0441\u0442 \u0433\u0440\u0438\u043f \u0410\/\u0412<\/td>5,11 \u20ac<\/td><\/tr>
\u0411\u044a\u0440\u0437 \u0430\u043d\u0442\u0438\u0433\u0435\u043d\u0435\u043d \u0442\u0435\u0441\u0442 13 \u0440\u0435\u0441\u043f\u0438\u0440\u0430\u0442\u043e\u0440\u043d\u0438 \u043f\u0430\u0442\u043e\u0433\u0435\u043d\u0430<\/td>18,00 \u20ac<\/td><\/tr>
\u041a\u043e\u043c\u0431\u0438\u043d\u0438\u0440\u0430\u043d \u0431\u044a\u0440\u0437 \u0442\u0435\u0441\u0442 Sars-Cov-2, \u0433\u0440\u0438\u043f \u0410\/\u0412<\/td>10,23 \u20ac<\/td><\/tr>
Chlamidophila pneumoniae IgA<\/td>16,87 \u20ac<\/td><\/tr>
Chlamidophila pneumoniae IgM<\/td>16,87 \u20ac<\/td><\/tr>
Chlamidophila pneumoniae IgG<\/td>16,87 \u20ac<\/td><\/tr>
Mycoplasma pneumoniae IgM<\/td>16,87 \u20ac<\/td><\/tr>
Mycoplasma pneumoniae Ig G<\/td>16,87 \u20ac<\/td><\/tr>
\u041b\u0435\u0433\u0438\u043e\u043d\u0435\u043b\u043e\u0437\u0430(Leginella Pneumophila)IgG(s1-6)<\/td>18,41 \u20ac<\/td><\/tr>
\u041b\u0435\u0433\u0438\u043e\u043d\u0435\u043b\u043e\u0437\u0430 (Legionella Pneumophila) IgM (s 1)<\/td>18,41 \u20ac<\/td><\/tr>
Q-\u0442\u0440\u0435\u0441\u043a\u0430 (Coxiella Burnetii, Q-fever) IgG<\/td>18,41 \u20ac<\/td><\/tr>
Q-\u0442\u0440\u0435\u0441\u043a\u0430 (Coxiella Burnetii, Q-fever) IgM<\/td>18,41 \u20ac<\/td><\/tr>
Coxiella Burnetii IgG\/M\/A IIF panel, ph.1+2<\/td>83,34 \u20ac<\/td><\/tr>
Q-\u0442\u0440\u0435\u0441\u043a\u0430 (Coxiella Burnetii, Q-fever) IgG IIF<\/td>43,46 \u20ac<\/td><\/tr>
Q-\u0442\u0440\u0435\u0441\u043a\u0430 (Coxiella Burnetii, Q-fever) IgM IIF<\/td>43,46 \u20ac<\/td><\/tr>
Q-\u0442\u0440\u0435\u0441\u043a\u0430 (Coxiella Burnetii, Q-fever) IgA IIF<\/td>43,46 \u20ac<\/td><\/tr>
\u041b\u0430\u0439\u043c\u0441\u043a\u0430 \u0431\u043e\u043b\u0435\u0441\u0442 ( anti Borrelia burgdorferi IgM )<\/td>12,78 \u20ac<\/td><\/tr>
\u041b\u0430\u0439\u043c\u0441\u043a\u0430 \u0431\u043e\u043b\u0435\u0441\u0442 ( anti Borrelia burgdorferi IgG )<\/td>12,78 \u20ac<\/td><\/tr>
\u041b\u0430\u0439\u043c\u0441\u043a\u0430 \u0431\u043e\u043b\u0435\u0441\u0442 Immunoblot IgM ( \u043f\u043e\u0442\u0432\u044a\u0440\u0434\u0438\u0442\u0435\u043b\u0435\u043d )<\/td>28,12 \u20ac<\/td><\/tr>
\u041b\u0430\u0439\u043c\u0441\u043a\u0430 \u0431\u043e\u043b\u0435\u0441\u0442 Immunoblot IgG ( \u043f\u043e\u0442\u0432\u044a\u0440\u0434\u0438\u0442\u0435\u043b\u0435\u043d )<\/td>28,12 \u20ac<\/td><\/tr>
\u0424\u0435\u043b\u0438\u043d\u043e\u0437\u0430 ( anti-Bartonella henselae IgM )<\/td>19,94 \u20ac<\/td><\/tr>
\u041c\u0430\u0440\u0441\u0438\u043b\u0441\u043a\u0430 \u0442\u0440\u0435\u0441\u043a\u0430 (Ricettsia conorii) IgM<\/td>16,87 \u20ac<\/td><\/tr>
\u041c\u0430\u0440\u0441\u0438\u043b\u0441\u043a\u0430 \u0442\u0440\u0435\u0441\u043a\u0430 (Rickettsia conorii) IgG<\/td>15,34 \u20ac<\/td><\/tr>
\u0411\u0440\u0443\u0446\u0435\u043b\u043e\u0437\u0430 (Brucella sp) Ig\u041c<\/td>16,87 \u20ac<\/td><\/tr>
\u0411\u0440\u0443\u0446\u0435\u043b\u043e\u0437\u0430 (Brucella sp) IgG<\/td>16,87 \u20ac<\/td><\/tr>
\u0420\u0443\u0431\u0435\u043e\u043b\u0430 IgM ( Rubeolla )<\/td>9,71 \u20ac<\/td><\/tr>
\u0420\u0443\u0431\u0435\u043e\u043b\u0430 IgG ( Rubeolla )<\/td>9,71 \u20ac<\/td><\/tr>
\u0412\u0430\u0440\u0438\u0446\u0435\u043b\u0430 \u0437\u043e\u0441\u0442\u0435\u0440 IgM ( Varicela zoster )<\/td>14,32 \u20ac<\/td><\/tr>
\u0412\u0430\u0440\u0438\u0446\u0435\u043b\u0430 \u0437\u043e\u0441\u0442\u0435\u0440 IgG ( Varicela zoster )<\/td>14,32 \u20ac<\/td><\/tr>
\u0426\u0438\u0442\u043e\u043c\u0435\u0433\u0430\u043b\u043e\u0432\u0438\u0440\u0443\u0441 IgM ( CMV IgM )<\/td>11,76 \u20ac<\/td><\/tr>
\u0426\u0438\u0442\u043e\u043c\u0435\u0433\u0430\u043b\u043e\u0432\u0438\u0440\u0443\u0441 IgG ( CMV IgG )<\/td>11,76 \u20ac<\/td><\/tr>
\u0426\u0438\u0442\u043e\u043c\u0435\u0433\u0430\u043b\u043e\u0432\u0438\u0440\u0443\u0441 (CMV) IgG+ avidity test<\/td>28,12 \u20ac<\/td><\/tr>
\u0426\u0438\u0442\u043e\u043c\u0435\u0433\u0430\u043b\u043e\u0432\u0438\u0440\u0443\u0441 CMV DNA<\/td>96,63 \u20ac<\/td><\/tr>
\u0411\u0440e\u043ce\u043d\u043d\u043e\u0441\u0442 TORCH\/CMV IgG, Rubeolla IgG,HSV2 IgG, Toxoplasmosa IgG<\/td>39,88 \u20ac<\/td><\/tr>
\u0418\u043c\u0443\u043d\u043e\u0431\u043b\u043e\u0442 \u0437\u0430 TORCH panel-Immunoblot IgG<\/td>33,75 \u20ac<\/td><\/tr>
\u0418\u043c\u0443\u043d\u043e\u0431\u043b\u043e\u0442 \u0437\u0430 TORCH panel-Immunoblot IgM<\/td>33,75 \u20ac<\/td><\/tr>
\u0418\u043d\u0444\u0435\u043a\u0446.\u043c\u043e\u043d\u043e\u043d\u0443\u043a\u043b. ( EBV VCA IgM )<\/td>12,27 \u20ac<\/td><\/tr>
\u0418\u043d\u0444\u0435\u043a\u0446.\u043c\u043e\u043d\u043e\u043d\u0443\u043a\u043b. ( EBV VCA IgG )<\/td>12,27 \u20ac<\/td><\/tr>
\u0418\u043d\u0444\u0435\u043a\u0446. \u043c\u043e\u043d\u043e\u043d\u0443\u043a\u043b. EBV EBNA IgG<\/td>13,29 \u20ac<\/td><\/tr>
\u0418\u043d\u0444\u0435\u043a\u0446. \u043c\u043e\u043d\u043e\u043d\u0443\u043a\u043b. EBV EA IgM<\/td>10,74 \u20ac<\/td><\/tr>
\u0418\u043d\u0444\u0435\u043a\u0446. \u043c\u043e\u043d\u043e\u043d\u0443\u043a\u043b. EBV EA IgG<\/td>10,74 \u20ac<\/td><\/tr>
EBV \u043a\u043e\u043b\u0438\u0447\u0435\u0441\u0442\u0432\u0435\u043d PCR ( Viral Load )<\/td>113,00 \u20ac<\/td><\/tr>
\u0415\u0431\u0449\u0430\u0439\u043d-\u0411\u0430\u0440-\u0412\u0438\u0440\u0443\u0441 EBV IgM Immunoblot<\/td>28,12 \u20ac<\/td><\/tr>
\u0415\u0431\u0449\u0430\u0439\u043d-\u0411\u0430\u0440-\u0412\u0438\u0440\u0443\u0441 EBV IgG Immunoblot<\/td>28,12 \u20ac<\/td><\/tr>
anti Helicobacter Pylori IgG ( \u0425\u0435\u043b\u0438\u043a\u043e\u0431\u0430\u043a\u0442\u0435\u0440 \u043f\u0438\u043b\u043e\u0440\u0438 ) \u043a\u0430\u0447\u0435\u0441\u0442\u0432\u0435\u043d \u0442\u0435\u0441\u0442<\/td>7,67 \u20ac<\/td><\/tr>
Helicobacter Pylori antigen ( \u0444\u0435\u0446\u0435\u0441 )\u043a\u0430\u0447\u0435\u0441\u0442\u0432\u0435\u043d \u0442\u0435\u0441\u0442<\/td>10,23 \u20ac<\/td><\/tr>
Helicobacter Pylori IgG ( \u0425\u0435\u043b\u0438\u043a\u043e\u0431\u0430\u043a\u0442\u0435\u0440 \u043f\u0438\u043b\u043e\u0440\u0438 ) \u043f\u043e\u043b\u0443\u043a\u043e\u043b\u0438\u0447\u0435\u0441\u0442\u0432\u0435\u043d \u0442\u0435\u0441\u0442<\/td>10,23 \u20ac<\/td><\/tr>
\u0425\u0435\u0440\u043f\u0435\u0441 \u0421\u0438\u043c\u043f\u043b\u0435\u043a\u0441 \u0442\u0438\u043f 1 IgM ( HSV 1 )<\/td>12,27 \u20ac<\/td><\/tr>
\u0425\u0435\u0440\u043f\u0435\u0441 \u0421\u0438\u043c\u043f\u043b\u0435\u043a\u0441 \u0442\u0438\u043f 1 IgG ( HSV 1 )<\/td>12,27 \u20ac<\/td><\/tr>
\u0425\u0435\u0440\u043f\u0435\u0441 \u0421\u0438\u043c\u043f\u043b\u0435\u043a\u0441 \u0442\u0438\u043f 2 IgM ( HSV 2 )<\/td>12,27 \u20ac<\/td><\/tr>
\u0425\u0435\u0440\u043f\u0435\u0441 \u0421\u0438\u043c\u043f\u043b\u0435\u043a\u0441 \u0442\u0438\u043f 2 IgG ( HSV 2 )<\/td>12,27 \u20ac<\/td><\/tr>
HHV-6 IgG ( \u0427\u043e\u0432\u0435\u0448\u043a\u0438 \u0425\u0435\u0440\u043f\u0435\u0441 \u0412\u0438\u0440\u0443\u0441-6 )<\/td>16,87 \u20ac<\/td><\/tr>
\u041c\u043e\u0440\u0431\u0438\u043b\u0438 IgM ( Morbili )<\/td>16,87 \u20ac<\/td><\/tr>
\u041c\u043e\u0440\u0431\u0438\u043b\u0438 IgG ( Morbili )<\/td>16,87 \u20ac<\/td><\/tr>
ParvovirusB19 IgM(\u041f\u0435\u0442\u0430 \u0431\u043e\u043b\u0435\u0441\u0442Erythema infectiosum)<\/td>15,34 \u20ac<\/td><\/tr>
\u041f\u0430\u0440\u043e\u0442\u0438\u0442 (\u0417\u0430\u0443\u0448\u043a\u0430) anti-Mumps IgM<\/td>14,32 \u20ac<\/td><\/tr>
\u041f\u0430\u0440\u043e\u0442\u0438\u0442 (\u0417\u0430\u0443\u0448\u043a\u0430) anti-Mumps IgG<\/td>14,32 \u20ac<\/td><\/tr><\/tbody><\/table><\/div>\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

\u0414\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0430 \u043d\u0430 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u043e\u0437\u043d\u0438 \u0431\u043e\u043b\u0435\u0441\u0442\u0438<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-346","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/mcselena.com\/index.php\/wp-json\/wp\/v2\/pages\/346","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mcselena.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/mcselena.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/mcselena.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mcselena.com\/index.php\/wp-json\/wp\/v2\/comments?post=346"}],"version-history":[{"count":4,"href":"https:\/\/mcselena.com\/index.php\/wp-json\/wp\/v2\/pages\/346\/revisions"}],"predecessor-version":[{"id":1383,"href":"https:\/\/mcselena.com\/index.php\/wp-json\/wp\/v2\/pages\/346\/revisions\/1383"}],"wp:attachment":[{"href":"https:\/\/mcselena.com\/index.php\/wp-json\/wp\/v2\/media?parent=346"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}